Navigation Links
Isis Pharmaceuticals And AstraZeneca Form Strategic Alliance On RNA Therapeutics For Cancer
Date:12/11/2012

xpectations, financial or other projections, intentions or beliefs, including the planned commercialization of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2011 and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Biogen Idec and Isis Pharmaceuticals Announce Collaboration For Antisense Programs To Treat Neurological Disorders
2. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
3. AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
5. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
6. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference
7. AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
8. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
9. Salix Pharmaceuticals Donates $500,000 To ASGEs IT&T Capital Campaign To Build A New State-of-the-Art GI Training Center
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Double-digit Growth Rate of the Pharmaceuticals Industry in Asia Pacific Boosts the API Market, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Dermatitis - India Drug Forecast and Market ... PharmaPoint: Atopic Dermatitis - ... 2022 Summary,Although the past decade ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ... including reductions in body fat content and preserved ...
(Date:1/14/2014)... HAMILTON, N.J. , Jan. 14, 2014 ... partnering event for buyers and sellers of high-value chemistry, ... annual conference at the Miami Beach ... http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) More than 3,500 ... companies will take part in the conference, which includes ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ("Global ... integrated pharmaceutical company engaged in pharmaceutical-related products distribution, ... business through its subsidiaries in Anhui, Jilin, Guangdong ... 31, 2011, it completed the acquisition of the ...
... Fla., Nov. 4, 2011 China Nuvo Solar Energy, ... signed an agreement with Bluewater Surgical, Inc. to a ... for spine surgery, sports medicine, trauma surgery and more ... as an alternative to the high priced medical device ...
Cached Medicine Technology:Global Pharm Holdings Group, Inc. Completes Acquisition of Qingdao Likang Pharmaceutical Co., Ltd. 2Global Pharm Holdings Group, Inc. Completes Acquisition of Qingdao Likang Pharmaceutical Co., Ltd. 3China Nuvo Solar Energy, Inc. Announces Third-Party Distribution Agreement With Bluewater Surgical, Inc. 2China Nuvo Solar Energy, Inc. Announces Third-Party Distribution Agreement With Bluewater Surgical, Inc. 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... instead of cooking at home continues to increase as ... large variety of food options and food establishments when ... available restaurants matter to Americas rising obesity" In a ... American Journal of Preventive Medicine, researchers found that the ...
... and lead to new treatments , , WEDNESDAY, Jan. ... anticipate and react to pain differently than women without ... of California, Los Angeles researchers found that women with ... in the brain, which makes them more sensitive to ...
... Stiffness for Better Health with,Innovative ,Sleep and Comfort, ... FORT LAUDERDALE, Fla., Jan. 9 Contour Products, ... implement an,ergonomic makeover into their life for more ... being. By aligning the body, relieving,pressure points and ...
... to Fight Plaque ... at Home, ... 14th annual Pets Need Dental Care, Too(TM) program, part of,February,s National Pet ... Need Dental Care, Too campaign fosters dental health for pets,by encouraging pet ...
... The most thorough study to date of the impact ... that this benefit led to a 13.1 percent decrease ... increase in prescription use. , Researchers from the University ... University used data from more than 117,000 patients to ...
... 8 In 2006, 66% of Americans were,overweight or ... working in,seated sedentary jobs? Or do we prefer seated ... No one knows for sure, but Texas based Neutral,Posture ... this trend. Recently,Neutral Posture introduced the Ntune(TM) Seating System, ...
Cached Medicine News:Health News:Eating out can have both positive and negative impact on obesity 2Health News:Women With IBS Unable to Switch Off Pain Response 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 2Health News:Renew, Relax & Align the Body with an Ergonomic Makeover 3Health News:Owners Reminded That Pets Need Dental Care, Too 2Health News:Owners Reminded That Pets Need Dental Care, Too 3Health News:First rigorous analysis defines impact of Medicare Part D 2Health News:Office Furniture That Helps Fight Fat! 2
... Bio-Rad isotopic anemia ... and minimal ,pipetting steps ... information about the processes ... and the benefit to ...
... The Zeus Scientific, Inc. ANA Screen ELISA test ... detect anti-nuclear antibodies (ANA) in human sera. When ... system is capable of detecting all ANAs commonly ... DNA (dsDNA), Jo-1, Sm, Sm/RNP, SSA, SSB, and ...
... Immuno Concepts manufactures slides that are ... technologist to decrease the number of pipetting ... patient sample dilutions on the slides. Ask ... procedure and these slides. These slide formats ...
... a patented HEp-2 cell line that has ... to SS-A/Ro autoantibodies, without affecting the other ... been published worldwide on the HEp-2000 ANA ... autoantibodies when used in place of standard ...
Medicine Products: